Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.

ABSTRACT:

SUBMITTER: Choughule A 

PROVIDER: S-EPMC4260019 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature